A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis (CFTY720D2399-LONGTERMS)

Published: 22-10-2010
Last updated: 04-05-2024

Primary: Safety and tolerability of fingolimod 0,5 mg.Secundairy: Long-term efficacy.Exploratory: Patient-Reported Outcomes Indices for Multiple Sclerosis (PRIMuS) and Short Form Health Survey*12 (SF-12), Treatment Satisfaction Questionnaire for...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Neurological disorders NEC
Study type	Interventional

Summary

ID

NL-OMON47187

Source
ToetsingOnline

Brief title
CFTY720D2399

Condition

- Neurological disorders NEC

Synonym
MS, multiple sclerosis

Research involving
Human

Sponsors and support

Primary sponsor: Novartis
Source(s) of monetary or material Support: Novartis Pharma BV

Intervention

Keyword: fingolimod, multiple sclerosis, safety, tolerability

Outcome measures

Primary outcome

Side effects. Special attention for ophthalmic and skin abnormalities.

Secondary outcome

Patient-Reported Outcomes Indices for Multiple Sclerosis (PRIMuS) en Short Form

Health Survey*12 (SF-12), Treatment Satisfaction Questionnaire for Medication

(TSQM-9).

Study description

Background summary

Fingolimod (FTY720) is a new oral treatment for multiple sclerosis (MS). The application for a market authorization has been submitted to the authorities.
It is an immunosupperssant. Fingolimod decreases the number of activated T-cells in blood and in the CNS by binding to the sphingosin-1-phosphate receptor-1 (S1P1) on circulating lymfocytes. This binding results in a reversible sequestration of T-cells, thus *trapping* autoagressive T-cells in peripheral lymoid tissues. Therefore they are not able to migrate to areas of inflammation in the CNS.
Fingolimod reduces the number of MS relapses and improves the MRI findings and inflammatory markers.
The current study is a follow-up study in order to collect additional long-term safety data and to enable patients from currently ongoing studies (relevant studies in NL: CFTY720D2316 en CFTY720D2301E1 (new patients are not eligible)) to continue using finglimod for up to 60 months (5 years) or until 30Jun2016.

The duration of 60 months (5 year) will be achieved first by all Dutch patients. Patients who are not eligible for reimbursement by health insurance at this time (and this is the situation in the Netherlands) are still allowed to use an additional 2 years fingolimod in this study. In the Netherlands, the end date of this study will be 30Jun2018.

Study objective

Primary: Safety and tolerability of fingolimod 0,5 mg.
Secundairy: Long-term efficacy.
Exploratory: Patient-Reported Outcomes Indices for Multiple Sclerosis (PRIMuS) and Short Form Health Survey*12 (SF-12), Treatment Satisfaction Questionnaire for Medication (TSQM-9).

Study design

Open, non-comparative phase IIIB safety study for patients coming from 2 ongoing studies in the Netherlands, with fingolimod 0,5 mg daily until the drug has obtained the registration and reimbursement status in the Netherlands. 1st dose of study medication will be given in the clinic. Monitoring during at least 6 h post intake of the 1st dose in case the patients did not use fingolimod during 14 days or more.
Approx. 5000 patients.

Intervention

Treatment with fingolimod.

Study burden and risks

Risks: Adverse effects of study medication.
Burden:
Part 1:
Visits every 3 months (year 1) and every 6 months thereafter. First visit = last visit of preceding study. During all visits vital signs, blood tests (10-15 ml per visits, during screening incl. HIV and hepatitis B-C) and pregnancy test (if relevant). Physical examination every 6 months and ophthalmalogical examination (incl. OCT measurement) yearly. Completion of SF12 and TSQM-9 (ex-CFTY720D2316) or EQ5D and Multiple Sclerosis Functional Composite (MSFC) (ex-CFTY720D2301E1) every 6 months.
Advice for monthly self-inspection of the skin.
MRI yearly for ex-CFTY720D2301E1 patients.
Part 2:
Deel 2:
Visits every 6 months. First visit = last visit of part 1. During all visits, vital signs, physical - and neurological examination, blood collection (10-15

ml each time + onze optional 10 ml extra for biomarker assessment). ECG at restart fingolimod. Only is case necessary according to investigator's opinion: PFT, dermatological examination, ophthalmalogical examination.

Contacts

Public
Novartis

Raapopseweg 1
Arnhem 6824 DP
NL
Scientific
Novartis

Raapopseweg 1
Arnhem 6824 DP
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Written informed consent must be obtained before any assessment is performed.
2. Patients who have completed designated ongoing or planned Novartis global clinical trials with fingolimod and are unable to obtain fingolimod outside a clinical trial.

Exclusion criteria

* Premature permanent discontinuation of a previous fingolimod study due to:
a. An adverse event or serious adverse event or laboratory abnormality.
b. Conditions leading to permanent study drug discontinuation such as macular edema, elevated liver enzymes five times ULN (upper limit of normal), malignancy of any organ system.
c. Unsatisfactory therapeutic result in the prceding fingolimod study (2 or more relapses per year as defined by the Dutch certified EC).
* Patients with a history of chronic disease of the immune system other than MS.
* Uncontrolled diabetes mellitus (HbA1c > 8%), certain forms of diabetic retinopathy.
* Patients with active systemic bacterial, viral or fungal infections. Positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
* Voorgaande behandeling met cladribine, cyclophosphamide of mitoxantrone.
* Immunosuppressive medications within 3 months prior to baseline.
* Immunoglobulins and/or monoclonal antibodies within 3 months prior to baseline.
* Cladribine, cyclophosphamide or mitoxantrone at any time.
* Any of the following cardiovascular conditions that have developed during the previous fingolimod study: history of cardiac arrest, MI in the last 6 months, unstable ischemic heart disease, cardiac failure (NYHA Class III), patients receiving current treatment with Class III antiarrhythmic drugs, history or presence of second type II or third degree AV block or corrected QTc interval >450 msec in males and >470 msec in females, proven history of sick sinus syndrome or sino-atrial heart block, uncontrolled hypertension, resting heart rate <45 bom, angina pectoris due to coronary spasm or Raynaud*s phenomenon.
* Pulmonary fibrosis, active tuberculosis.
* Pregnancy, lactation, inadequate contraception.
Patients who temporarily or permanently discontinued from any fingolimod study because of pregnancy or nursing (lactating) can be re-enrolled.

Study design

Design

Study phase:	3
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	22-12-2010
Enrollment:	95
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Gilenia
Generic name:	fingolimod
Registration:	Yes - NL intended use

Ethics review

Approved WMO Date:	22-10-2010
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	01-12-2010
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	09-02-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	14-02-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	05-09-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Approved WMO Date:	16-01-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	01-02-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-02-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	24-04-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-04-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	02-11-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-05-2013
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	29-10-2013
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	26-11-2013
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	

Date:	06-02-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-02-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	17-06-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	14-11-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-07-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	29-07-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	25-11-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	07-12-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	04-05-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	

Date:	20-05-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	06-06-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	12-06-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	26-10-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	28-05-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	18-06-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2010-020515-37-NL
ClinicalTrials.gov	NCT01201356
CCMO	NL33502.029.10